Long‐term clinical and immunological effects of p53‐SLP® vaccine in patients with ovarian cancer
Abstract
Vaccine‐induced p53‐specific immune responses were previously reported to be associated with improved response to secondary chemotherapy in patients with small cell lung cancer. We investigated long‐term clinical and immunological effects of the p53‐synthetic long peptide (p53‐SLP®) vaccine in patients with recurrent ovarian cancer. Twenty patients were immunized with the p53‐SLP® vaccine between July 2006 and August 2007. Follow‐up information on patients was obtained. Clinical responses to secondary chemotherapy after p53‐SLP® immunizations were determined by computerized tomography and/or tumor marker levels (CA125). Disease‐specific survival was compared to a matched historical control group. Immune responses were analyzed by flow cytometry, proliferation assay, interferon gamma (IFN‐γ) ELISPOT and/or cytokine bead array. Lymphocytes cultured from skin biopsy were analyzed by flow cytometry and proliferation assay. Of 20 patients treated with the p53‐SLP® vaccine, 17 were subsequently treated with chemotherapy. Eight of these patients volunteered another blood sample. No differences in clinical response rates to secondary chemotherapy or disease‐specific survival were observed between immunized patients and historical controls (p = 0.925, resp. p = 0.601). p53‐specific proliferative responses were observed in 5/8 patients and IFN‐γ production in 2/7 patients. Lymphocytes cultured from a prior injection site showing inflammation during chemotherapy did not recognize p53‐SLP®. Thus, treatment with the p53‐SLP® vaccine does not affect responses to secondary chemotherapy or survival, although p53‐specific T‐cells do survive chemotherapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A subsequent clinical trial by Leffers and co-workers in 2012 failed to show any benefit over historical controls.
“However, a subsequent clinical trial conducted by Leffers and co-workers in 2012 failed to show any benefit over historical controls.590”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [590]
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works
Rustin, G. J. S., Vergote, I. B., Eisenhauer, E. A., Pujade-Lauraine, É., Quinn, M. A., Thigpen, T., du Bois, A., Kristensen, G. B., Jakobsen, A. K. M., Sagae, S., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182070f17 · Cited by 625 · see citing works
Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444 · see citing works
Welters, M. J. P., Kenter, G. G., Piersma, S. J., Vloon, A. P. G., Löwik, M. J. G., der Meer, D. M. A. B.-V., Drijfhout, J. W., Valentijn, A. R. P. M., Wafelman, A. R., Oostendorp, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1880 · Cited by 374 · see citing works
Leffers, N., Lambeck, A. J. A., Gooden, M. J. M., Hoogeboom, B. N., Wolf, R., Hamming, I. L. E., Hepkema, B. G., Willemse, P. H. B., Molmans, B. H. W., Hollema, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24597 · Cited by 141 · see citing works
Self-citationSvane, I. M., Pedersen, A. E., Johnsen, H. E., Nielsen, D. L., Kamby, C., Gaarsdal, E., Nikolajsen, K., Buus, S., & Claësson, M. H. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0493-5 · Cited by 114 · see citing works
Svane, I. M., Pedersen, A. E., Johansen, J. S., Johnsen, H. E., Nielsen, D. L., Kamby, C., Ottesen, S., Balslev, E., Gaarsdal, E., Nikolajsen, K., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0293-4 · Cited by 104 · see citing works
van der Burg, S. H., Menon, A. G., Redeker, A., Bonnet, M.-C., Drijfhout, J. W., Tollenaar, R. A. �. �., van de Velde, C. J. �., Moingeon, P. E., Kuppen, P. J. K., Offringa, R., et al. (2002) · PubMed · Cited by 90 · see citing works
Advances in carriers and adjuvants for veterinary biologics
Stott, J. (1987) · Preventive Veterinary Medicine · doi:10.1016/0167-5877(87)90008-0 · Cited by 51 · see citing works
Lambeck, A. J. A., Leffers, N., Hoogeboom, B. N., Sluiter, W. J., Hamming, I. L. E., Klip, H. G., ten Hoor, K. A., Esajas, M. D., van Oven, M., Drijfhout, J. W., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22710 · Cited by 34 · see citing works
Self-citationTreatment of recurrent small cell lung cancer
Davies, A. M., Evans, W. K., Mackay, J. A., & Shepherd, F. A. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2003.12.010 · Cited by 26 · see citing works
Ferrari, S., Malugani, F., Rovati, B., Porta, C., Riccardi, A., & Danova, M. (2005) · PubMed · Cited by 24 · see citing works
Herrin, V. E., Achtar, M. S., Steinberg, S. M., Whiteside, T. L., Wieckowski, E., Czystowska, M., Visús, C., Berzofsky, J. A., & Khleif, S. N. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3011 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 736 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333 · see citing works
Chemoresistance and targeted therapies in ovarian and endometrial cancers
Brasseur, K., Gévry, N. Y., & Asselin, É. (2016) · Oncotarget · doi:10.18632/oncotarget.14021 · Cited by 224 · see citing works
“Following analyses indicated that the administration of P53-SLP did not enhance the efficiency of chemotherapy treatments, thus was not able to overcome the chemoresistance of advanced ovarian cancer patients [293].”
BackgroundRodriguez, G. M., Galpin, K. J. C., McCloskey, C. W., & Vanderhyden, B. C. (2018) · Cancers · doi:10.3390/cancers10080242 · Cited by 139 · see citing works
“wild-type human p53 (p53MVA) + gemcitabine [48] Synthetic long peptide (SLP) vaccine [49]”
BackgroundNext-generation peptide vaccines for advanced cancer
Yamada, A., Sasada, T., Noguchi, M., & Itoh, K. (2013) · Cancer Science · doi:10.1111/cas.12050 · Cited by 124 · see citing works
Turning Tumors into Vaccines: Co-opting the Innate Immune System
van den Boorn, J. G., & Hartmann, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.011 · Cited by 103 · see citing works
Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study
Vermeij, R., Leffers, N., Hoogeboom, B. N., Hamming, I. L. E., Wolf, R., Reyners, A. K. L., Molmans, B. H. W., Hollema, H., Bart, J., Drijfhout, J. W., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27388 · Cited by 97 · see citing works
Self-citationImmune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
Weir, G. M., Liwski, R., & Mansour, M. (2011) · Cancers · doi:10.3390/cancers3033114 · Cited by 81 · see citing works
“reported no benefits to secondary chemotherapy in ovarian cancer patients that had previously received a p53-synthetic long peptide (SLP)® vaccine, despite observing a significant benefit to NSCLC patients [97].”
BackgroundOverexpressed oncogenic tumor-self antigens
Bright, R. K., Bright, J. D., & Byrne, J. A. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29475 · Cited by 65 · see citing works
Takahashi, N., Ohkuri, T., Homma, S., Ohtake, J., Wakita, D., Togashi, Y., Kitamura, H., Todo, S., & Nishimura, T. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2011.02106.x · Cited by 61 · see citing works
Immunotherapy for Ovarian Cancer
Drerup, J. M., Yang, L., Padron, A. S., Murthy, K., Hurez, V. J., Zhang, B., & Curiel, T. J. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0317-1 · Cited by 58 · see citing works
Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers
Tucci, C. D., Schiavi, M. C., Faiano, P., D’Oria, O., Prata, G., Sciuga, V., Giannini, A., Palaia, I., Muzii, L., & Panici, P. B. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.05.011 · Cited by 57 · see citing works
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Lluesma, S. M., Wolfer, A., Harari, A., & Kandalaft, L. E. (2016) · Biomedicines · doi:10.3390/biomedicines4020010 · Cited by 59 · see citing works
“Phase II; (Leffers, 2012 [49]) 20 OvCa pts (HLA indep) No difference in survival between p53-SLP treated pts and historical controls (median 44.”
BackgroundMethodResultInfluentialImmunotherapy in ovarian cancer
Mantia-Smaldone, G. M., Corr, B. R., & Chu, C. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.20738 · Cited by 54 · see citing works
“Further, p53SLP vaccination did not have long-term impact on responses to secondary chemotherapy or survival in this cohort of patients.(33) In a second phase II trial, the authors combined the p53-SLP vaccine with cyclophosphamide with the aim of targeting Tregs and thereby improving the immunogenicity of the vaccine.”
BackgroundThe Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
Wallis, B., Bowman, K. E. R., Lu, P., & Lim, C. S. (2023) · Biomolecules · doi:10.3390/biom13010159 · Cited by 53 · see citing works
Hardwick, N. R., Carroll, M., Kaltcheva, T., Qian, D., Lim, D., Leong, L., Chu, P., Kim, J., Chao, J., Fakih, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3361 · Cited by 45 · see citing works
Antigen-specific active immunotherapy for ovarian cancer
Leffers, N., Daemen, T., Helfrich, W., Boezen, H. M., Cohlen, B. J., Melief, C. J. M., & Nijman, H. W. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007287.pub3 · Cited by 42 · see citing works
Self-citationJohnson, R. L., Cummings, M., Thangavelu, A., Theophilou, G., Jong, D. D., & Orsi, N. M. (2021) · Cancers · doi:10.3390/cancers13246231 · Cited by 39 · see citing works
Development of Therapeutic Vaccines for Ovarian Cancer
Chow, S. K.-Y., Berek, J. S., & Dorigo, O. (2020) · Vaccines · doi:10.3390/vaccines8040657 · Cited by 39 · see citing works
Dafni, U., Lluesma, S. M., Balint, K., Tsourti, Z., Vervita, K., Chenal, J., Coukos, G., Zaman, K., Sarivalasis, A., & Kandalaft, L. E. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.014 · Cited by 38 · see citing works
Radiation and Anti-Cancer Vaccines: A Winning Combination
Cadena, A. P., Cushman, T. R., Anderson, C., Barsoumian, H. B., Welsh, J. S., & Cortez, M. A. (2018) · Vaccines · doi:10.3390/vaccines6010009 · Cited by 34 · see citing works
Specific Immunotherapy in Ovarian Cancer: A Systematic Review
Aalipour, S., Zoghi, S., Khalili, N., Hirbod‐Mobarakeh, A., Emens, L. A., & Rezaei, N. (2016) · Immunotherapy · doi:10.2217/imt-2016-0034 · Cited by 30 · see citing works
Clinical and Immunological Effects of p53-Targeting Vaccines
Zhou, S., Fan, C., Zeng, Z., Young, K. H., & Li, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.762796 · Cited by 28 · see citing works
“The p53-SLP vaccine combined with cyclophosphamide therapy is evaluated by Vermeij et al. for treating patients with recurrent ovarian cancer in a single-arm phase II study (Vermeij et al., 2012).”
BackgroundInfluentialChauhan, S., Jaiswal, S., Jakhmola, V., Singh, B. P., Bhattacharya, S., Garg, M., & Sengupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216766 · Cited by 28 · see citing works
Mechanisms of Peptide Vaccination in Mouse Models
van Hall, T., & van der Burg, S. H. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00003-2 · Cited by 28 · see citing works
“…restricted to viral antigens per se as phase I/II trials in patients with colorectal cancer and ovarian cancer have shown that SLP vaccines comprising ‘‘self’’-p53 sequences display the capacity to induce T-cell responses with similar robustness (Leffers et al., 2009, 2012; Speetjens et al., 2009).”
BackgroundAspord, C., Leloup, C., Reche, S., & Plumas, J. (2014) · European Journal of Immunology · doi:10.1002/eji.201444588 · Cited by 24 · see citing works
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 25 · see citing works
Immunotherapy of gynecological cancers
Matanes, E., & Gotlieb, W. H. (2019) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2019.03.005 · Cited by 22 · see citing works
Antigen-specific active immunotherapy for ovarian cancer
Paijens, S. T., Leffers, N., Daemen, T., Helfrich, W., Boezen, H. M., Cohlen, B. J., Melief, C. J. M., de Bruyn, M., & Nijman, H. W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007287.pub4 · Cited by 21 · see citing works
Self-citationDou, Y., Jansen, D. T. S. L., van den Bosch, A., de Man, R. A., van Montfoort, N., Araman, C., van Kasteren, S. I., Zom, G. G., Krebber, W.-J., Melief, C. J. M., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104746 · Cited by 20 · see citing works
“…(SLP®)-based vaccines show favourable results for the treatment of human papilloma virus (HPV) induced cancers by triggering HPV-specific T cell responses (Dijkgraaf et al., 2015; Kenter et al., 2009; Leffers et al., 2012; van Poelgeest et al., 2016; Vermeij et al., 2012; Welters et al., 2016).”
BackgroundPeptides for diagnosis and treatment of ovarian cancer
Guo, L., Wang, J., Li, N., Cui, J., & Su, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135523 · Cited by 18 · see citing works
“A number of peptide vaccines against ovarian cancer are currently in clinical trials (Table 4), such as NY-ESO-1 peptide vaccine (116), folic acid receptor a peptide vaccine (120), HER-2/neu peptide vaccine (117), P53 synthetic long peptide vaccine (p53-SLP) (118), and WT1 peptide vaccine (119).”
BackgroundSingh, V. K., Werner, S., Hackstein, H., Lennerz, V., Reiter, A., Wölfel, T., Damm‐Welk, C., & Woessmann, W. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12842 · Cited by 13 · see citing works
Singh, V. K., Werner, S., Schwalm, S., Lennerz, V., Ruf, S., Stadler, S., Hackstein, H., Reiter, A., Wölfel, T., Damm‐Welk, C., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1625688 · Cited by 12 · see citing works
Immune Checkpoint Blockers and Ovarian Cancer.
Bose, C. K. (2017) · PubMed Central · doi:10.4103/ijmpo.ijmpo_73_16 · Cited by 10 · see citing works
“26 months).[23,24] Strong positive correlation is observed between the levels of CD8+ T‐cells and granzyme B within tumors.”
BackgroundPreclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
Martínez, A., Delord, J., Ayyoub, M., & Devaud, C. (2020) · Cancers · doi:10.3390/cancers12071761 · Cited by 11 · see citing works
Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives
Mehrotra, M., Phadte, P., Shenoy, P. S., Chakraborty, S., Gupta, S., & Ray, P. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-58311-7_4 · Cited by 9 · see citing works
Lekshmy, M., Dhanya, C. R., Satheeshkumar, S. J., Sindhurani, J. A., Vandanamthadathil, J. J., Veettil, J. T., Anila, L., Vishnu, S. K., Nayar, A. M., & Madhavan, M. (2023) · Pharmaceuticals · doi:10.3390/ph16071054 · Cited by 9 · see citing works
“p53-SLP® vaccine Montanide ISA51, Subcutaneous Vaccination followed by chemotherapy p53-specific IFN-γ ↑ Clinical trial Phase II Epithelial ovarian cancer N = 17 [105]”
The Role of the Immune System in Ovarian Cancer and Implications on Therapy
Menderes, G., Schwab, C. L., Black, J., & Santin, A. D. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1147957 · Cited by 7 · see citing works
Immune checkpoints, their control by immunotherapy and ovarian cancer
Bose, C. K. (2017) · Współczesna Onkologia · doi:10.5114/wo.2017.70108 · Cited by 5 · see citing works
Peptide and Protein-Based Cancer Vaccines
Braun, M., Perret, R., Scholz, G., & Romero, P. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_5 · Cited by 5 · see citing works
Insights on Peptide Vaccines in Cancer Immunotherapy
Tsang, K. Y., Jochéms, C., & Schlom, J. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-21167-1_1 · Cited by 5 · see citing works
Nucleic acid‐based vaccine for ovarian cancer cells; bench to bedside
Al‐Hawary, S. I. S., Jasim, S. A., Hjazi, A. M., Oghenemaro, E. F., Kaur, I., Kumar, A., Al‐Ani, A. M., Alwaily, E. R., Redhee, A. H., & Mustafa, Y. F. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3978 · Cited by 4 · see citing works
Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer
Yazdi, M. T., Keene, K., Hiemstra, P., & van der Burg, S. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.862499 · Cited by 5 · see citing works
Preclinical support for tumor protein D52 as a cancer vaccine antigen
Bright, R. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2273699 · Cited by 3 · see citing works
The guardian of the genome meets immunotherapy: p53-based strategies
Savostyanova, T. A., Lopatnikova, J., & Sennikov, S. V. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1762679 · Cited by 2 · see citing works
Ovarian cancer: Targeted therapies and mechanisms of resistance
Sarvepalli, D., Rashid, M. U., Zafar, H., Jehanzeb, S., Zahid, E., & Ahmad, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824299-5.00014-9 · Cited by 2 · see citing works
Ovarian Cancer from an Immune Perspective
Zakharia, Y., Rahma, O. E., & Khleif, S. N. (2014) · Radiation Research · doi:10.1667/rr13741.1 · Cited by 2 · see citing works
“However, the vaccine did not show any effect on survival or tumor response (52, 53).”
BackgroundWeir, G. M. (2016) · DalSpace (Dalhousie University)
The Future in Ovarian Cancer: Advances in Immunotherapies
Makkouk, A., Chester, C., & Kohrt, H. E. K. (2016) · Springer eBooks · doi:10.1007/978-3-319-32110-3_11
Exploiting synthetic lethality in ovarian cancer
O'Donnell, R. L. (2016)
Martin, L. P., & Schilder, R. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803741-6.00008-2
Padron, A. S., Murthy, K., Hurez, V. J., Zhang, B., & Curiel, T. J. (2015)
Najjar, E. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.17.002991
“It induced a significant immunologic response in most patients and was found to be well tolerated [16,17].”
BackgroundLe patriarche de Ferney et les salons féminins de Paris
Menissier, P. (2006) · Travaux de littérature
Immunotherapy in gynecologic malignancies
Renz, M., & Dorigo, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-77684-4.00026-x
Berzofsky, J. A., Olkhanud, P. B., & Maeng, H. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00014-1
Efficacy analysis of targeted P53 therapy in solid tumors
Wang, P., & Wang, F. (2025) · Medical Oncology · doi:10.1007/s12032-025-02930-y
“However, due to the lack of significant activation of CD8+ T cells, further in-depth research was not carried out, which may be related to the low affinity of CD8+ TCR [92, 93].”
Targeting p53 for immunotherapy of solid tumors
Филипенко, М. Л., Boyarskikh, U. A., & Kushlinskii, N. E. (2026) · Advances in molecular oncology · doi:10.17650/2313-805x-2026-13-1-8-15
- Authors
- Leffers, N., Vermeij, R., Hoogeboom, B., Schulze, U. R., Wolf, R., Hamming, I. E., van der Zee, A. G., Melief, K. J., van der Burg, S. H., Daemen, T., & Nijman, H. W.
- Affiliations
- University Medical Center Groningen (NL)
- Medisch Centrum Leeuwarden (NL)
- Corresponding author
- Nijman, Hans W.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-05-09
- Volume
- 130
- Issue
- 1
- Pages
- 105-112
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2127039405
- Cited by
- 60
- References
- 13
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 3 · 2023: 6 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 8 · 2015: 3 · 2014: 5 · 2013: 2 · 2012: 5
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- ovarian cancer, recurrent ovarian cancer, cancer immunotherapy, disease-specific survival, interferon-gamma, CA125, vaccine-induced immune response
- MeSH terms
- Antineoplastic Agents, Adenocarcinoma, Mucinous, Female, Flow Cytometry, Follow-Up Studies, Humans, Immunization, Interferon-gamma, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Peptide Fragments, Prospective Studies, T-Lymphocytes, Tumor Suppressor Protein p53, Cytokines, Endometrial Neoplasms, Adenocarcinoma, Clear Cell, Cystadenocarcinoma, Serous, CA-125 Antigen, Cancer Vaccines, Cell Proliferation, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
